CoChat

Use of Renin-Angiotensin Inhibitors in People with Renal Artery Stenosis

Open access
Evans, Kaleigh L., Tuttle, Katherine R., Folt, David A., Dawson, Taylor, Haller, Steven T., Brewster, Pamela S., He, Wencan, Jamerson, Kenneth, Dworkin, Lance D., Cutlip, Donald E., Murphy, Timothy P., D’Agostino, Ralph B., Henrich, William, Cooper, Christopher J. · 2014 · Clinical Journal of the American Society of Nephrology
Cited by 45

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

BACKGROUND AND OBJECTIVES: People with atherosclerotic renal artery stenosis may benefit from renin-angiotensin inhibitors, angiotensin-converting enzyme inhibitors, and angiotensin-receptor blockers, but little is known about the factors associated with their use. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The Cardiovascular Outcomes in Renal Atherosclerotic Lesions study (ClinicalTrials.gov identified: NCT00081731) is a prospective, international, multicenter clinical trial that randomly assigned participants with atherosclerotic renal artery stenosis who received optimal medical therapy to stenting versus no stenting from May 2005 through January 2010. At baseline, medication information was available from 853 of 931 randomly assigned participants. Kidney function was measured by serum creatinine-based eGFR at a core laboratory. RESULTS: Before randomization, renin-angiotensin inhibitors were used in 419 (49%) of the 853 participants. Renin-angiotensin inhibitor use was lower in those with CKD (eGFR<60 ml/min per 1.73 m(2)) (58% versus 68%; P=0.004) and higher in individuals with diabetes (41% versus 27%; P<0.001). Presence of bilateral renal artery stenosis or congestive heart failure was not associated with renin-angiotensin inhibitor use. Although therapy with renin-angiotensin inhibitors varied by study site, differences in rates of use were not related to the characteristics of the site participants. Participants receiving a renin-angiotensin inhibitor had lower systolic BP (mean ± SD, 148 ± 23 versus 152 ± 23 mmHg; P=0.003) and more often had BP at goal (30% versus 22%; P=0.01). CONCLUSIONS: Kidney function and diabetes were associated with renin-angiotensin inhibitor use. However, these or other clinical characteristics did not explain variability among study sites. Patients with renal artery stenosis who received renin-angiotensin inhibitor treatment had lower BP and were more likely to be at treatment goal.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2215/cjn.11611113

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 33

  1. Hansen, 2002, Prevalence of renovascular disease in the elderly:A population-based study., J Vasc Surg, 36, 443, 10.1067/mva.2002.127351 · DOI · Paper page
  2. Kalra, 2005, Atherosclerotic renovascular disease in United States patients aged 67 years or older: risk factors, revascularization, and prognosis., Kidney Int, 68, 293, 10.1111/j.1523-1755.2005.00406.x · DOI · Paper page
  3. Kalra, 2010, Atherosclerotic renovascular disease in the United States., Kidney Int, 77, 37, 10.1038/ki.2009.406 · DOI
  4. Lao, 2011, Atherosclerotic renal artery stenosis—diagnosis and treatment., Mayo Clin Proc, 86, 649, 10.4065/mcp.2011.0181 · DOI
  5. Long, 2004, How does angiotensin II cause renal injury?, Hypertension, 43, 722, 10.1161/01.HYP.0000120964.22281.3e · doi:10.1161/01.hyp.0000120964.22281.3e
  6. Lonn, 1994, Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection., Circulation, 90, 2056, 10.1161/01.CIR.90.4.2056 · DOI · Paper page
  7. Johnson, 2008, Pathogenesis of essential hypertension: Historical paradigms and modern insights., J Hypertens, 26, 381, 10.1097/HJH.0b013e3282f29876 · DOI
  8. Tokuyama, 2002, Differential regulation of elevated renal angiotensin II in chronic renal ischemia., Hypertension, 40, 34, 10.1161/01.HYP.0000022060.13995.ED · doi:10.1161/01.hyp.0000022060.13995.ed
  9. Montecucco, 2009, The renin-angiotensin system modulates inflammatory processes in atherosclerosis: Evidence from basic research and clinical studies., Mediators Inflamm, 2009, 752406, 10.1155/2009/752406 · DOI
  10. Akers, 2000, Renin-angiotensin system and sympathetic nervous system in cardiac pressure-overload hypertrophy., Am J Physiol Heart Circ Physiol, 279, H2797, 10.1152/ajpheart.2000.279.6.H2797 · DOI
  11. Hricik, 1983, Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney., N Engl J Med, 308, 373, 10.1056/NEJM198302173080706 · DOI · Paper page
  12. Bart, 1997, Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction., Am J Cardiol, 79, 1118, 10.1016/S0002-9149(97)00060-X · DOI
  13. van de Ven, 1998, Angiotensin converting enzyme inhibitor-induced renal dysfunction in atherosclerotic renovascular disease., Kidney Int, 53, 986, 10.1111/j.1523-1755.1998.00840.x · DOI
  14. Ahmed, 2002, Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: How concerned should we be by the rise in serum creatinine?, J Am Geriatr Soc, 50, 1297, 10.1046/j.1532-5415.2002.50321.x · DOI
  15. Chrysochou, 2012, Dispelling the myth: the use of renin-angiotensin blockade in atheromatous renovascular disease., Nephrol Dial Transplant, 27, 1403, 10.1093/ndt/gfr496 · DOI · Paper page
  16. Losito, 2005, Long-term follow-up of atherosclerotic renovascular disease. Beneficial effect of ACE inhibition., Nephrol Dial Transplant, 20, 1604, 10.1093/ndt/gfh865 · DOI · Paper page
  17. Calhoun, 2008, Resistant hypertension: diagnosis, evaluation, and treatment: A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research., Circulation, 117, e510, 10.1161/CIRCULATIONAHA.108.189141 · DOI · Paper page
  18. Chobanian, 2003, The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report., JAMA, 289, 2560, 10.1001/jama.289.19.2560 · DOI · Paper page
  19. Foley, 2007, End-stage renal disease in the United States: An update from the United States Renal Data System., J Am Soc Nephrol, 18, 2644, 10.1681/ASN.2007020220 · DOI · Paper page
  20. Guo, 2007, Atherosclerotic renovascular disease in older US patients starting dialysis, 1996 to 2001., Circulation, 115, 50, 10.1161/CIRCULATIONAHA.106.637751 · DOI
  21. de Silva, 2007, Epidemiology, associated factors, and prognostic outcomes of renal artery stenosis in chronic heart failure assessed by magnetic resonance angiography., Am J Cardiol, 100, 273, 10.1016/j.amjcard.2007.02.098 · DOI
  22. Yancy, 2013, 2013 ACCF/AHA guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines., Circulation, 128, 1810, 10.1161/CIR.0b013e31829e8807 · DOI · Paper page
  23. de Mast, 2009, The prevalence of atherosclerotic renal artery stenosis in risk groups: A systematic literature review., J Hypertens, 27, 1333, 10.1097/HJH.0b013e328329bbf4 · DOI · Paper page
  24. Bourantas, 2012, Atherosclerotic disease of the abdominal aorta and its branches: Prognostic implications in patients with heart failure., Heart Fail Rev, 17, 229, 10.1007/s10741-011-9284-9 · DOI
  25. Cooper, 2006, Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial., Am Heart J, 152, 59, 10.1016/j.ahj.2005.09.011 · DOI · Paper page
  26. Wheatley, 2009, Revascularization versus medical therapy for renal-artery stenosis., N Engl J Med, 361, 1953, 10.1056/NEJMoa0905368 · DOI · Paper page
  27. Bax, 2009, Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: A randomized trial., Ann Intern Med, 150, 840, 10.7326/0003-4819-150-12-200906160-00119 · DOI · Paper page
  28. Ravid, 1993, Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients., Ann Intern Med, 118, 577, 10.7326/0003-4819-118-8-199304150-00001 · DOI · Paper page
  29. Mogensen, 2000, Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study., BMJ, 321, 1440, 10.1136/bmj.321.7274.1440 · DOI · Paper page
  30. Keyhani, 2008, Gender disparities in blood pressure control and cardiovascular care in a national sample of ambulatory care visits., Hypertension, 51, 1149, 10.1161/HYPERTENSIONAHA.107.107342 · DOI · Paper page
  31. Rocha-Singh, 2005, Evaluation of the safety and effectiveness of renal artery stenting after unsuccessful balloon angioplasty: The ASPIRE-2 study., J Am Coll Cardiol, 46, 776, 10.1016/j.jacc.2004.11.073 · DOI · Paper page
  32. Jaff, 2012, Significant reduction in systolic blood pressure following renal artery stenting in patients with uncontrolled hypertension: Results from the HERCULES trial., Catheter Cardiovasc Interv, 80, 343, 10.1002/ccd.24449 · DOI · Paper page
  33. Rocha-Singh, 2008, Renal artery stenting with noninvasive duplex ultrasound follow-up: 3-year results from the RENAISSANCE renal stent trial., Catheter Cardiovasc Interv, 72, 853, 10.1002/ccd.21749 · DOI

Cited by

See all 45

Metadata

Authors
Evans, K. L., Tuttle, K. R., Folt, D. A., Dawson, T., Haller, S. T., Brewster, P. S., He, W., Jamerson, K., Dworkin, L. D., Cutlip, D. E., Murphy, T. P., D’Agostino, R. B., Henrich, W., & Cooper, C. J.
Venue
Clinical Journal of the American Society of Nephrology
Published
2014-07
Volume
9
Issue
7
Pages
1199-1206
ISSN
1555-9041 (ISSN-L)
OpenAlex
W2149633685
Cited by
45
References
4
FWCI
2.91
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.